Review article: explaining risks of inflammatory bowel disease therapy to patients

• Published in: Alimentary pharmacology & therapeutics Vol. 33; no. 1; pp. 23 - 32
• Main Author: Siegel, C. A.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.01.2011; Blackwell
• Subjects: Adrenal Cortex Hormones - adverse effects; Biological and medical sciences; Combined Modality Therapy - adverse effects; Communication; Digestive system; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Immunologic Factors - adverse effects; Inflammatory Bowel Diseases - complications; Inflammatory Bowel Diseases - drug therapy; Medical sciences; Other diseases. Semiology; Patient Education as Topic; Pharmacology. Drug treatments; Physician-Patient Relations; Risk Factors; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Human; Inflammatory bowel disease; Crohn disease; Treatment; Risk factor; Digestive diseases; Intestinal disease; Review; Bibliographic review; Inflammatory disease; Ulcerative colitis
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/j.1365-2036.2010.04489.x

Aliment Pharmacol Ther 2011; 33: 23–32 Summary Background  Medical treatment for inflammatory bowel disease (IBD) has advanced significantly over the past decade, but it is important to communicate effectively the balance of benefits and risks of therapy to patients to facilitate informed medical decisions. Aim  To review the available data describing the risk of side effects of IBD medications and to describe effective methods for communicating risk. Methods  To identify relevant articles for this review, a PubMed search was conducted using relevant key words and phrases. In addition, reference lists from identified manuscripts were searched and recent s from National meetings were reviewed. Results  The steroid‐sparing medications used for the treatment of IBD all carry risks of both common and rare adverse events. Trade‐offs need to be made between the risks of these medications vs. the risks of poorly treated disease and corticosteroids. There has been significant research on how best to present risk data to patients, which is summarized in this review. Conclusions  To ensure that our patients understand their choices and feel comfortable with their treatment, we need to communicate risk data to patients clearly. Patients comprehend absolute numbers better than relative risk, and when available, pictorial representations of data are preferred over solely presenting numerical outcomes.